stockportfolio.pro
BridgeBio Oncology Therapeutics, Inc. (BBOT)
Healthcare · Biotechnology · NasdaqGM
BridgeBio Oncology Therapeutics, Inc. revenue & earnings — last 3 fiscal years
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Gross profit | — | — | — |
| Net income | $-64.70M | $-74.28M | $-134.04M |
| Net margin | — | — | — |
Source: BridgeBio Oncology Therapeutics, Inc. SEC filings (10-K).
Explore 3 years of BridgeBio Oncology Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track BBOT in your portfolio →
BridgeBio Oncology Therapeutics, Inc. financial history by metric
About BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
BridgeBio Oncology Therapeutics, Inc. — frequently asked questions
What is BridgeBio Oncology Therapeutics, Inc.'s revenue?
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is BridgeBio Oncology Therapeutics, Inc. profitable?
No — BBOT reported a net loss of $-134.04M in fiscal 2025.
What is BBOT's P/E ratio?
BridgeBio Oncology Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does BridgeBio Oncology Therapeutics, Inc. have?
As of fiscal year 2025, BBOT carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is BridgeBio Oncology Therapeutics, Inc.'s market cap?
BridgeBio Oncology Therapeutics, Inc. (BBOT) has a market capitalization of about $599.20M, based on the latest data in our nightly-refreshed cache.
When does BridgeBio Oncology Therapeutics, Inc.'s fiscal year end?
BBOT's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from BridgeBio Oncology Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 3 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.